EUVIMEDEUVIMED entdecken
Crossref

What Does the EU HTA Regulation Mean for the Approval and Benefit Assessment of Neuropsychopharmaceuticals?

Karl Broich, Marion Haberkamp, Antje Behring, Georgios Aislaitner, Wiebke Löbker

Psychopharmakotherapie · 2025

DOI: 10.52778/ppt20250021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Psychopharmakotherapie, 2025. Verfasst von Karl Broich und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Broich, K., Haberkamp, M., Behring, A., Aislaitner, G., & Löbker, W. (2025). What Does the EU HTA Regulation Mean for the Approval and Benefit Assessment of Neuropsychopharmaceuticals?. Psychopharmakotherapie. https://doi.org/10.52778/ppt20250021

Vancouver

Broich K, Haberkamp M, Behring A, Aislaitner G, Löbker W. What Does the EU HTA Regulation Mean for the Approval and Benefit Assessment of Neuropsychopharmaceuticals?. Psychopharmakotherapie. 2025. doi:10.52778/ppt20250021

BibTeX
@article{Broich2025,
  author = {Broich, Karl and Haberkamp, Marion and Behring, Antje and Aislaitner, Georgios and Löbker, Wiebke},
  title = {What Does the EU HTA Regulation Mean for the Approval and Benefit Assessment of Neuropsychopharmaceuticals?},
  journal = {Psychopharmakotherapie},
  year = {2025},
  doi = {10.52778/ppt20250021}
}
Kostenlos starten →